Leinco Technologies Inc. completes acquisition of QED Biosciences to expand antibody capabilities
09/03/24, 3:14 PM
Location
fentonsan diegoIndustry
manufacturing
biotechnology
health care
Leinco Technologies has acquired QED Biosciences, a leading provider of antibodies, kits, and recombinant proteins and antigens. This strategic acquisition will enable Leinco to expand its portfolio of antibody capabilities used globally for research and diagnostics, targeting the IVD and research sectors.
Company Info
Location
Fenton, Missouri, United States
Company info
Established in 1992, Leinco Technologies is a specialty manufacturer of early discovery research products, including antibodies, recombinant proteins, ELISA kits, and other life sciences products. Additionally, the company offers a full suite of custom development and manufacturing services and serves leading drug discovery and in vitro diagnostic companies around the world. Headquartered outside of St. Louis, Missouri, Leinco operates out of a 27,000 square foot facility with significant laboratory space to service all customer and regulatory requirements.